For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201217:nRSQ8784Ia&default-theme=true
RNS Number : 8784I Accrol Group Holdings PLC 17 December 2020
17 December 2020
ACCROL GROUP HOLDINGS PLC
("Accrol", the "Company" or the "Group")
AIM: ACRL
NOTICE OF HALF YEAR RESULTS
Accrol Group, one of the UK's leading independent tissue converters, announces
that it will release its Half Year Results for the six months to 31 October
2020 on Tuesday, 12 January 2021.
An analyst briefing will be held online at 9.00 am on that day. Equity
analysts interested in joining the meeting should contact Belvedere
Communications, see contact details below.
A webinar presentation for retail investors will also be held as part of the
results roadshow. Details of this event will be announced in due course.
For further information, please contact:
Accrol Group Holdings plc
Dan Wright, Executive Chairman Via Belvedere Communications
Gareth Jenkins, Chief Executive Officer
Zeus Capital Limited (Nominated Adviser & Broker)
Dan Bate / Jordan Warburton Tel: +44 (0) 161 831 1512
Dominic King / John Goold Tel: +44 (0) 203 829 5000
Liberum Capital Limited (Joint Broker) Tel: +44 (0) 20 3100 2222
Clayton Bush / Edward Thomas
Belvedere Communications Limited
Cat Valentine Tel: +44 (0) 7715 769 078
Keeley Clarke Tel: +44 (0) 7967 816 525
Llew Angus Tel: +44 (0) 7407 023 147
accrolpr@belvederepr.com
Overview of Accrol
Accrol Group Holdings plc is a leading tissue converter and supplier of toilet
tissues, kitchen rolls and facial tissues to many of the UK's leading
discounters and grocery retailers across the UK. Following the recent
acquisition of a state-of-the-art tissue converter based in Leicester, the
Group now operates from five sites, including four in Lancashire, which
generate revenues totalling c.16% of the £1.7bn UK retail tissue market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORFQLFFBLLEFBF